{"entity":{"id":"nct02480374","kind":"trial","name":"Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer","aka":[],"tldr":"A phase 1 trial of IMNN-001 run by Imunon, completed.","summary":"Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer is a phase 1 interventional study registered as NCT02480374 by Imunon, with 18 participants enrolled, started 2015-09. Conditions recorded: Epithelial Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer. Interventions recorded: IMNN-001.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02480374","url":"https://clinicaltrials.gov/study/NCT02480374"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["imnn-001"],"companies":["imunon"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02480374","phase":"1","setting":"A Phase I Study of the Safety and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer","sponsor":"Imunon","enrolled":18,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02480374/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"imnn-001","kind":"drug","name":"IMNN-001","route":"/drugs/imnn-001/"}],"company":[{"id":"imunon","kind":"company","name":"Imunon","route":"/companies/imunon/"}]}}